Evidence-Based Medicine at New York Biotechnology Association 2009 annual meeting(NYBA).
Sarah Evans moderated the highly successful Evidence-Based Medicine panel on April 20th.
The panel speakers included, Dr Renee Arnold, Prof Mount Sinai Medical School, who gave an over view of Evidence-Based Medicine: How will it Shape Healthcare in the coming Decades.
Stuart McConchie, VP Jarvik Heart speaking on behalf of the medical device industry.
Teresa Zyczynski, PharmD, MBA, Senior Director Health economics & Outcomes Research, GE Heathcare, Diagnostics.
Dr Jaiwei Xuan, from Pfizer, representing the mature pharmaceutical industry.
According to the Institute of Medicine Roundtable on Evidence-Based Medicine, with "per capita expenditures more than 20 percent higher than any other country in the world and more than twice the average expenditure for European countries, the nation ranks well below at least two dozen others on key health indices such as infant survival and life expectancy." What's the problem? Lack of application of the best evidence to medical decision-making, both to individual patients and to patient populations as a whole. Will we have government regulation imposed on us, such as the U.K.'s National Institute for Health and clinical Excellence (NICE), the NHS' cost-effectiveness watchdog? Can we monitor ourselves using well-established methods, such as outcomes registries, retrospective database analysis and cost-effectiveness analysis, to generate the evidence we need to rein in our spiraling healthcare costs, while improving patient outcomes?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment